I
IASO Biotherapeutics
Focused on the discovery, development and commercialization of cell therapies in the field of oncology
About IASO Biotherapeutics
IASO Biotherapeutics, founded in 2017, is a clinical-stage biopharmaceutical company specializing in the development and commercialization of cell therapies for oncological and autoimmune diseases. The company's core focus is on Chimeric Antigen Receptor (CAR)-T cell therapies, with a pipeline that includes candidates for various conditions.
Read full description
A key product in their portfolio is Equecabtagene Autoleucel (also known as CT103A), a fully human BCMA CAR-T therapy for the treatment of relapsed/refractory multiple myeloma (RRMM). The company has presented data showing promising efficacy for this treatment. Beyond oncology, IASO is exploring the application of its cell therapies in autoimmune diseases, with studies underway for conditions such as multiple sclerosis (MS).
The company manages the entire lifecycle of its therapies, from initial discovery and development to manufacturing and eventual commercialization. It has received Investigational New Drug (IND) application approvals from regulatory bodies, including the FDA in the United States, allowing it to conduct clinical trials and advance its therapeutic candidates.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- China
- Employees
- 50
- Open positions
- 2
- Dealroom signal
- 86.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning IASO Biotherapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| FundingOther financing | Jul 2024 | $0 | — | Innovent Biologics | ↗ |
| SERIES COther financing | Jan 2023 | $74M | $540M | Guoxin Investment · Houxin Jiantou Private Equity Fund Management · Hongcheng Capital · Shanghai Wai Gaoqiao Free Trade Zone Development | ↗ |
Growth signals
Latest recorded traffic for IASO Biotherapeutics is 4.3K monthly website visits, up 115% over the last three months. IASO Biotherapeutics's team grew 11.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Longevity Fund
Hillhouse Capital
Series B and later13 investors entered at this stage
CDH Investments
CCB International
China Everbright Limited- CCCo-Stone Capital
GL Ventures
Plaisance Capital
CNCB Capital- GIGuoxin Investment
- HMHouxin Jiantou Private Equity Fund Management
- HCHongcheng Capital
- SDShanghai Wai Gaoqiao Free Trade Zone Development
Nanjing Yang Zi State-Owned Investment Group- YCYifeng Capital
Other known investors1 additional known investor
Innovent Biologics
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about IASO Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See IASO Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.